CARB-X receives $50m from UK & Gates; Session at BIO on antibiotic reimbursement; PLOS opens an AMR Channel; CDD-sponsored SAR webinar

Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list…

  • CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds, CARB-X has raised more than $500 million. And the money is being applied at a furious pace: from its launch 21 months ago on 28 July 2016, CARB-X has funded 36 companies!! Showing that the projects are moving swiftly and the portfolio is being actively managed, 33 are still being funded and 3 have reached a project endpoint.
  • Antibiotic economics at BIO: The anti-infective track at the BIO meeting shows sessions that cover bacteria, fungi, and viruses. Note in particular these two:
  • PLOS announced that it has collaborated with GARDP to launch an AMR channel. Described as a global forum for AMR research, the press release says that the channel will provide research, commentaries, blogs, news, and discussions that span science, research and development, public health, and policy.
  • CDD (Collaborative Drug Discovery) will host a webinar on at 11a EST on 26 June on “SAR data in Drug Discovery”. Andrew Leach (ChEMBL) and Evan Bolton (PubChem) will discuss drug discovery informatics and ways to use the freely available PubChem and ChEMBL SAR data. This webinar is not specifically focused on AMR but rather looks like a good broad tour of tools that make SAR information more accessible.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

How economists (and Finance Ministers) think…

Dear All, Anthony McDonnell and his colleagues at CGD (Center for Global Development) have just released a truly lovely paper on the economics of antibiotic resistance. What makes this one special is that the paper dissects the problem of AMR through an economist’s spectacles in a way that is very accessible to the non-expert. You

The road to UNGA 2024 is paved with … reports!

Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024

Leaving the lab: The decline in AMR R&D professionals

Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going

ADVANCE-ID seeks antibiotic for P2/3 development Asia!

Dear All, Yow! Led by David Paterson,  ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic

Scroll to Top